文献速递浆细胞疾病

意义未明单克隆丙种球蛋白病与冒烟型多发性骨髓瘤诊疗范式的转变

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
PubMed 文献 · Leukemia · 2020-10-12

本文综述MGUS与SMM的流行病学、风险分层模型及向MM进展的预测因素,讨论MM遗传异质性与克隆演化、肿瘤细胞与骨髓微环境互作,并概述当前管理推荐与早期干预临床试验带来的争议。

要点

  • MGUS与SMM是MM必然经历的前驱阶段,需风险分层预测进展。
  • 高效低毒新药使早期干预是否改变自然病史成为开放争议。
  • 当前管理推荐与早期干预试验结果需结合风险分层个体化决策。

核心结论

  • MGUS和SMM是MM连续疾病谱的前驱阶段,风险分层与早期干预是当前核心争议。

研究设计与样本

  • 综述,讨论MGUS和SMM的流行病学、风险分层模型、遗传异质性与克隆演化、骨髓微环境及管理推荐。

主要发现

  • 过去二十年在前驱浆细胞疾病的遗传特征和风险分层方面取得显著进展。
  • MM存在遗传异质性、克隆演化及肿瘤细胞与骨髓微环境的相互作用。
  • 早期干预临床试验结果使MGUS和SMM的管理争议受到关注。

临床怎么用

  • 对MGUS和SMM患者应基于风险分层预测进展并参考当前管理推荐。
  • 早期治疗决策需权衡早期干预临床试验结果与开放争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a highly heterogenous disease that exists along a continuous disease spectrum starting with premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) that inevitably precede MM. Over the past two decades, significant progress has been made in the genetic characterization and risk stratification of precursor plasma cell disorders. Indeed, the clinical introduction of highly effective and well-tolerated drugs begs the question: would earlier therapeutic intervention with novel therapies in MGUS and SMM patients alter natural history, providing a potential curative option? In this review, we discuss the epidemiology of MGUS and SMM and current models for risk stratification that predict MGUS and SMM progression to MM. We further discuss genetic heterogeneity and clonal evolution in MM and the interplay between tumor cells and the bone marrow (BM) microenvironment. Finally, we provide an overview of the current recommendations for the management of MGUS and SMM and discuss the open controversies in the field in light of promising results from early intervention clinical trials.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ho M, Patel A, Goh CY, et al. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020. PMID: 33046818. doi:10.1038/s41375-020-01051-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。